Species | SARS-CoV-2 | ||||||
Protein Construction |
Expressed with the mutations of E484K, K417N, N501Y.
|
||||||
Purity | > 90% as analyzed by SDS-PAGE | ||||||
Endotoxin Level | < 0.2 EU/μg of protein by gel clotting method | ||||||
Biological Activity | SARS-CoV-2 Spike protein (RBD, E484K, K417T, N501Y, Avi & His Tag) can bind with human ACE2 in functional ELISA assay. | ||||||
Expression System | CHO | ||||||
Theoretical Molecular Weight | 33.7 kDa | ||||||
Formulation | Supplied as a solution in PBS, pH 7.4. | ||||||
Concentration | Please refer to the COA for the specific lot. | ||||||
Storage & Stability | Upon receiving, this product remains stable for up to 6 months at -20°C or below. Please avoid repeated freeze-thaw cycles. |
Target Background | SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Lineage P.1, also known as the Brazil(ian) variant is one of the variants of SARS-CoV-2. This variant has 17 amino acid changes, ten of which are in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T. SARS-CoV-2 Spike protein (RBD, E484K, K417T, N501Y, Avi & His Tag) carries a Avi Tag followed by a polyhistidine tag at the C-terminus. It has high binding affinity to human chimeric ACE2. |
Synonyms | Lineage P.1; 20J/501Y.V3; VOC-202101/02; Brazil(ian) variant; Gamma variant |
References |
1. Variants: distribution of cases data. GOV.UK. Retrieved 27 February 2021. 2. COVID-19: Virologist says Brazilian coronavirus variant detected in UK is not the one 'of concern'. 3. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
For more documents, please visit "Technical Support".